US Biobanks Market 2026 – 2035

The market size of global soft tissue repair is estimated to be USD 17.6 billion in 2025, and it is estimated that such a market size will rise to USD 18.1 billion in 2026, and to around USD 26.5 billion in 2035, at an annual CAGR of 6.4% between the years 2026 and 2035. Market expansion is primarily driven by the rapid growth of precision medicine, regenerative medicine, oncology research, and population-based genomics programs across the United States.

The growing need for high-quality biospecimens such as tissues, blood, DNA, RNA and cells in pharmaceutical R&D, biomarker discovery, and clinical trials is further driving the use of biobanks.

Market Highlight

• Human tissue samples accounted for over 38.4% of total market revenue in 2025, supported by extensive use in oncology, pathology, and translational research.

• By application, genomics and precision medicine are expected to record the highest CAGR of 6.5% from 2026 to 2035, driven by population genomics and sequencing initiatives.

• Pharmaceutical and biotechnology companies represented approximately 42.5% of total end-use demand in 2025, reflecting rising reliance on external biobanking services for R&D.

Significant Growth Factors

The US biobanks market Trends present significant growth opportunities due to several factors:

• Growth of Precision Medicine and Genomics Research: The US healthcare sector experiences a surge in the use of precision medicine, which depends on large, well-annotated biospecimen collections. The long-term demand for biobank services is growing as the national programs including population genomics programs, cancer moonshot programs, and rare diseases registries, grow. These programs need to have standardized biosample collection, long term cryogenic storage and sophisticated data integration. The US spends more than USD 45 billion per year on biomedical research, with genomics and oncology taking a significant portion of biospecimen-based research.

• Expanding Pharmaceutical and Biotechnology Research and Development: Increasing drug discovery programs, biologics programs, and cell and gene therapy programs are intensifying the demand for disease biosamples. To avoid the complexity of operation and ensure meeting regulatory requirements, pharmaceutical companies are progressively contracting the services of accredited biobanks to store and manage samples. The companion diagnostics, biomarker validation studies, and clinical trials now include biobanks. More than 70% of biospecimen management in Phase II-III trials mandates biobank support, and more than 50% of clinical trials around the world have their trials on US soil.

• Expanding Burden of Chronic and Rare Diseases: Long term biosample collection efforts are motivated by the increased prevalence of cancer, cardiovascular diseases, neurological disorders, and autoimmune conditions. Biobanks that focus on diseases facilitate longitudinal studies that aid in the early detection of diseases, individualized therapy designs, and research models that are outcome-based. The biobanks of rare diseases are becoming increasingly strategic because of orphan drug development incentives. The US has a demand of biospecimen repositories of 1.9 million new cancer patients each year and an excess of patients with rare diseases which demands continuous usage of repositories.

What are the Major Advances Changing the US biobanks market Today?

• High Operational and Infrastructure Costs: Biobank operations involve a high cost in terms of capital and operational expenses due to the need to have high-quality cryogenic storage, automation systems, quality control procedures, and sample tracking with the help of IT. Small institutions are likely to have difficulties with growing biobank infrastructure while being compliant with regulations and preserving sample integrity. The US alone can cost an establishment of a large biobank facility USD 5-15 million, not to mention the costs that are incurred in its upkeep, power, and compliance.

• Ethical, Consent, and Data Privacy: The use of human biospecimens has ethical issues of informed consent, data possession, and sample secondary use. The international cooperation that is aligned with the HIPAA requirements, the international collaboration outlined by the GDPR, and the new consent frameworks also contribute to the complexity of the biobank governance models. Over 60 percent of research-related protocols of biobanks receive further IRB review, which adds more time and administrative expenses to the approval process.

• Standardization and Sample Quality Variability: The degree of variation in the methods of sample collection, storage, and standards of annotation has an effect upon the reproducibility of research findings. Absence of consistent SOP implementation in the decentralized biobank networks has been a hindrance towards data interoperability and mass collaborative studies. It is found that a proportion of up to 20.30% of biosamples stored in archives can be affected without a standardized set of preservation guidelines.

Category Wise Insights

By Sample Type

Why Human Tissue Samples Dominate the US Biobanks Market?

The US biobanks market is the biggest market mainly because human tissue samples are the most important in modelling diseases, pathology, and research translationally. Firm tissues play an important role in the cancer profiling, histology, and molecular characterization of disease processes. Demand has been increased by the growing interest in the tumor microenvironment and heterogeneity that has been high. Tissue based research has been heavily funded with cancer still being among the biggest causes of death in the US. Moreover, new progress in the preservation of tissues is enhancing durability of use, which strengthens the leadership of this segment.

Why Nucleic Acids Are the Fastest-Growing Sample Segment?

The DNA and RNA samples are anticipated to experience the most growth over the forecast period as genomic sequencing and molecular diagnostics are growing rapidly. The large-scale nucleic acid repositories that have standardized measures of quality are needed in population genomics projects and in rare disease studies. Demand is further accelerated by the falling price of sequencing and the increasing popularity of the liquid biopsy methods. The storage and transportation of nucleic acids are scalable to research on a national and multi-center level, and sample storage and transportation are easier than that of tissues.

By Application

Why Genomics and Precision Medicine Lead the Market?

The prevailing application area is genomics and precision medicine because the US has been leading in the research of personalized healthcare. The genomes associated with genome-wide association studies, pharmacogenomics, and biomarker discovery all use biobanks as their foundation. The combination of genomic data and electronic health records is allowing more in-depth disease progression and treatment reaction understanding. The adoption is still growing faster under federal projects and private investments, which makes this segment the key source of revenue.

Why Drug Discovery and Development Is the Fastest-Growing Application?

The drug discovery will experience the largest CAGR because drug discoveries are increasingly looking at human-derived samples as a way of enhancing preclinical validation and decreasing late-stage clinical failures. Biobanks are used to access disease-specific cohorts, which make them better in terms of target validation and translational relevance. The change to biologics and cell-based therapies further enhances the dependency on high-quality biospecimens in all phases of the development lifecycle.

By End Use

Why Pharmaceutical and Biotechnology Companies Dominate End Use?

The largest end user is pharmaceutical and biotechnology companies, as they require scalable access to biospecimens and have lengthy R&D pipelines. Biobanking outsourcing saves time to market and regulatory quality sample processing. The growing demand in these organizations is strategic collaboration with biobanks with built-in data analysis and cohort personalization, which enhances demand in the long run.

Why Contract Research Organizations Are the Fastest-Growing End Users?

The CROs are also becoming the fastest-growing end-use segment, with sponsors outsourcing trial management and sample logistics. CROs use centralized biobanking solutions, allowing them to support multi-site trials and provide geographical consistency. This trend is being increased by the development of decentralized and adaptive trials.

Report Scope

Key Developments

The market has undergone significant developments as industry participants seek to expand capabilities and enhance product portfolios.

• In February 2025, Discovery Life Sciences strengthened its US biobanking network, increasing access to oncology and rare disease biospecimens in pharmaceutical research.

• In December 2024, Thermo Fisher Scientific enhanced its biobanking automation offerings, which enabled sample processing on large-scale genomics initiatives with high throughput.

These strategic activities have allowed companies to strengthen market positions, expand product offerings, enhance technological capabilities, and capitalize on growth opportunities within the expanding market.